Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43846   clinical trials with a EudraCT protocol, of which   7282   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-001466-21
    Sponsor's Protocol Code Number:61364
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2019-10-09
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2017-001466-21
    A.3Full title of the trial
    Multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke. The effect of periprocedural medication: acetylsalicylic acid, unfractionated heparin, both or neither
    Essai clinique randomisé multicentrique du traitement endovasculaire de l’accident vasculaire cérébrale ischémique aigu. Effet du traitement médicamenteux péri-interventionnel : acide acétylsalicylique, héparine non fractionnée, les deux ou aucun
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke. The effect of periprocedural medication: acetylsalicylic acid, unfractionated heparin, both or neither
    Essai clinique randomisé multicentrique du traitement endovasculaire de l’accident vasculaire cérébrale ischémique aigu. Effet du traitement médicamenteux péri-interventionnel : acide acétylsalicylique, héparine non fractionnée, les deux ou aucun
    A.3.2Name or abbreviated title of the trial where available
    MR CLEAN - MED
    MR CLEAN - MED
    A.4.1Sponsor's protocol code number61364
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorErasmus MC University Medical Center
    B.1.3.4CountryNetherlands
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportDutch Heart Foundation
    B.4.2CountryNetherlands
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationErasmus MC University Medical Center
    B.5.2Functional name of contact pointDWJ Dippel, neurologist
    B.5.3 Address:
    B.5.3.1Street Addresswytemaweg 80
    B.5.3.2Town/ cityRotterdam
    B.5.3.3Post code3015 CN
    B.5.3.4CountryNetherlands
    B.5.6E-maild.dippel@erasmusmc.nl
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Unfractionated heparin (generic)
    D.2.1.2Country which granted the Marketing AuthorisationFrance
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameheparin
    D.3.4Pharmaceutical form Injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Aspegic (Acetylsalicylic acid)
    D.2.1.2Country which granted the Marketing AuthorisationFrance
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAspegic
    D.3.4Pharmaceutical form Injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Acute ischemic stroke
    Accident vasculaire cérébrale ischémique aigu
    E.1.1.1Medical condition in easily understood language
    Acute ischemic stroke
    Accident vasculaire cérébrale ischémique aigu
    E.1.1.2Therapeutic area Diseases [C] - Cardiovascular Diseases [C14]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level LLT
    E.1.2Classification code 10055221
    E.1.2Term Ischemic stroke
    E.1.2System Organ Class 100000004852
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this trial to assess the effect of unfractionated heparin and acetylsalicylic acid, alone, or in combination on functional outcome at 3 months in patients with AIS caused by a confirmed intracranial large vessel occlusion of the anterior circulation, who undergo intra-arterial treatment with or without prior intravenous thrombolysis according to standard care. Control patients will receive usual care alone (EVT with or without IVT), without additional periprocedural use of unfractioned heparin or acetylsalicylic acid, followed by analysis for stroke etiology, secondary preventive measures and rehabilitation.
    L’objectif primaire est d’évaluer l’effet de l’héparine non fractionnée et de l’acide acétylsalicylique, seuls ou en association, sur l’évolution fonctionnelle à 3 mois chez les patients ayant eu un AVC ischémique aigu dû à l’occlusion confirmée d’un vaisseau intracrânien antérieur de large calibre et ayant reçu un traitement intra-artériel précédé ou pas par une thrombolyse selon la pratique courante. Les patients contrôle recevront le traitement habituel seul (traitement endovasculaire avec ou sans thrombolyse intraveineuse), sans administration additionnelle péri-interventionnelle d'héparine non fractionnée ou d'acide acétylsalicylique suivie par l'analyse étiologique de l'AVC, des mesures préventives secondaires et de la réhabilitation.
    E.2.2Secondary objectives of the trial
    The secondary objective is to assess the safety and effect of unfractionated heparin and acetylsalicylic acid, alone, or in combination, on neurological outcome, revascularization and infarct size in patients who undergo intra-arterial treatment for AIS caused by a confirmed intracranial large vessel occlusion of the anterior circulation.
    L’objectif secondaire est d’évaluer la sécurité et l’effet de l’héparine non fractionnée et de l’acide acétylsalicylique, seuls ou en association, sur l’évolution neurologique, la revascularisation et la taille de l’infarctus chez les patients ayant reçu un traitement intra-artériel pour AVC ischémique aigu dû à l’occlusion confirmée d’un vaisseau intracrânien antérieur de large calibre.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - a clinical diagnosis of acute ischemic stroke;
    - caused by intracranial large vessel occlusion of the anterior circulation
    (distal intracranial carotid artery or middle (M1/proximal M2) cerebral
    artery confirmed by neuro-imaging (CTA or MRA);
    - CT or MRI ruling out intracranial hemorrhage;
    - treatment possible (groin puncture) within 6 hours from symptom
    onset or last seen well;
    - a score of at least 2 on the NIH Stroke Scale;
    - age of 18 years or older;
    - written informed consent (deferred).
    - Diagnostic d’AVC ischémique aigu
    - Causé par l’occlusion d’un vaisseau intracrânien antérieur de large calibre (artère carotide intracrânienne distale ou artère cérébrale moyenne (segments M1/M2 proximal)) confirmée par neuro-imagerie (angio-scanner ou angio-IRM) ;
    - Scanner ou IRM éliminant une hémorragie intracrânienne ;
    - Traitement possible (ponction de l’aine) dans les 6 heures depuis le début des symptômes ou la dernière fois en bon état ;
    - Score NIHSS ≥ 2 ;
    - Age ≥ 18 ans ;
    - Ayant signé le consentement éclairé écrit (différé).
    E.4Principal exclusion criteria
    - Pre-stroke disability which interferes with the assessment of functional
    outcome at 90 days, i.e. mRS >2
    - (Relative) contra-indications for ASA/unfractionated heparin, including: allergy, recent surgery, heparin induced thrombocytopenia, pregnancy
    - INR exceeding 3.0
    - Known hemorrhagic diathesis or known thrombopenia (<90^9/L)
    - Treatment with IV alteplase despite the following contra-indications for
    IV alteplase:
    o cerebral infarction in the previous 6 weeks with residual neurological
    deficit or signs of recent infarction on neuroimaging,
    o previous intracerebral hemorrhage within the previous 3 months,
    o INR exceeding 1.7,
    o prior use of direct oral anticoagulant (DOAC),
    - IV alteplase infusion >4.5 hours after symptom onset.
    - therapeutic heparin use
    - Participation in medical or surgical intervention trials other than
    current (or MR ASAP / ARTEMIS)
    - Handicap pré-infarctus qui interfère avec l’évaluation fonctionnelle à 90 jours, ex. mRS > 2 ;
    - Traitement avec alteplase intraveineuse malgré les contrindications suivantes pour l’alteplase intraveineuse :
    o Infarctus cérébral dans les 6 semaines précédentes avec déficit neurologique résiduel ou signes d’infarctus récent sur la neuroimagerie ;
    o Hémorragie intracérébrale dans les 3 mois précédents ;
    o INR dépassant 1,7 ;
    o Précédente administration d’anticoagulants oraux directs (AOD) ;
    o Perfusion d’alteplase intraveineuse > 4,5 heures après le début des symptômes.
    - (Relative) Contrindications pour acide acétylsalicylique/héparine non fractionnée, incluant : allergie, chirurgie récente, thrombocytopénie induite par l’héparine, grossesse ;
    - Utilisation d’héparine thérapeutique ;
    - INR dépassant 3,0 ;
    - Diathèses hémorragique ou thrombocytopénie (<909/L) connues ;
    - Participation à une recherche clinique interventionnelle de type médicament ou chirurgicale autre que la présente (ou MR ASAP / ARTEMIS aux Pays-Bas).
    E.5 End points
    E.5.1Primary end point(s)
    90 days (± 14 days).30 The mRS is the preferred disability parameter of
    clinical trials in stroke. The mRS is an ordinal hierarchical scale
    incorporating six categories from 0 up to and including 5, and describes
    the range of disability encountered post stroke. 'Death' is assigned a
    score of 6.
    Le critère d’évaluation principal est le score de Rankin modifié (mRs) à 90 jours (± 14 jours) après l’inclusion dans l’étude.
    E.5.1.1Timepoint(s) of evaluation of this end point
    90 days
    90 jours
    E.5.2Secondary end point(s)
    - Extended treatment in cerebral ischaemia (eTICI) score on final
    angiography of IAT (Table 2)
    - Recanalization rate at 24 hours, assessed with CTA
    - Score on the NIHSS at 24 hours and 5-7 days, or at discharge
    - Final infarct volume at 5-7 days, assessed with NCCT or MRI in a subset
    of 600 patients. Final infarct volume will be assessed with the use of an
    automated, validated algorithm. Infarct size at day 5-7 will be compared
    with plain CT and perfusion CT results (if available) at baseline.
    - Dichotomized mRS of 0-1 vs. 2-6 at 90 days (± 14 days)
    - Dichotomized mRS of 0-2 vs. 3-6 at 90 days (± 14 days)
    - Dichotomized mRS of 0-3 vs. 4-6 at 90 days (± 14 days)
    - Score on the EQ-5D-5L and Barthel index at 90 days (± 14 days)
    Safety endpoints are the following:
    - Intracerebral hemorrhage according to the Heidelberg Bleeding
    Classification
    - Symptomatic intracerebral hemorrhage (sICH) scored according to the
    Heidelberg Bleeding Classification, with the addition of sICH that led to
    death and that was identified as the predominant cause of the neurologic
    deterioration
    - Major extracranial hemorrhages requiring transfusion or resulting in death
    - Embolization in new territory on angiography during IAT
    - Infarction in new territory within 5-7 days
    Les critères d’évaluation secondaire incluent la mortalité à 90 jours, la gravité de l’AVC mesurée par le score National Institutes of Health Stroke (NIHSS) à 24 heures et 5-7 jours, la recanalisation via l’angiographie de soustraction digitale postinterventionnelle (mesurée par le score de recanalisation eTICI) et via le scanner à 24 +/- 12 heures ou IRM à 24-48 heures et la taille de l’infarctus à 5-7 jours, ou 24-48 heures si IRM effectuée, et mRS dichotomisé, décès, score du EQ-5D-5L et index de Barthel à 90 jours.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Mostly at 90 days
    Majoritairement à 90 jours
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    essai PROBE
    PROBE design
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Prise en charge habituelle
    Standard care
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA22
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS and
    The study will only be terminated prematurely if the Data Safety
    Monitoring Board recommends stopping. In case of premature
    termination of the study the database will be closed after 90 days
    assessment of the last enrolled patient and results will be reported
    Dernière visite dernier patient et
    L'étude sera arrêtée prématurément uniquement si le Comité de Surveillance Indépendant propose l’arrêt. En cas d’arrêt prématuré de l'étude, la base de données sera clôturée après l'évaluation à 90 jours du dernier patient inclus et les résultats seront colligés.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 750
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 750
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the database on 2019-10-09. Yes
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women Yes
    F.3.3.5Emergency situation Yes
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Stroke patients may have cognitive problems or aphasia due to their stroke, which prevents them from understanding benefits and risks of this trial. If those patients would be excluded, the results cannot be extrapolated to all stroke patients.
    Les patients avec AVC peuvent avoir des problèmes cognitifs ou une aphasie, les empêchant de comprendre bénéfices et risques de l’étude. Si ces patients étaient exclus, les résultats ne pourraient pas être extrapolés à tous les patients avec AVC.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state400
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 1500
    F.4.2.2In the whole clinical trial 1500
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Not different from the expected normal treatment of ischemic stroke
    Pas différent de la prise en charge habituelle de l'AVC ischémique
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-02-07
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-01-09
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 19 09:32:06 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA